Immunization

Study concludes vaccine significantly reduces risk of herpes zoster.

Moderna is upping its COVID-19 vaccine production this year, with a baseline estimation of 600 million doses for 2021.

In a statement, FDA officials recommended that all health care professionals continue to adhere to the FDA-authorized dosing and schedules of the COVID-19 vaccines.

With support from Operation Warp Speed and the National Institutes of Health, the study will evaluate the safety and efficacy of NVX-CoV2373.

Here are some of the top-read FDA approvals covered by Drug Topics® from this year.

The Drug Topics® team rounded up some of our top-read articles from the last year.

The FDA has authorized the Moderna mRNA vaccine for emergency use, making it the second vaccine for COVID-19.

Extra vaccine multidose vials may boost the country’s supply by millions of doses.

US health care workers have started receiving the COVID-19 vaccine, but we are still months away from approving the vaccine for use in children, according to Fauci.

The program is designed to provide immunization administration training to hundreds of thousands of pharmacy technicians within weeks.

The FDA has granted emergency use authorization (EUA) to the Pfizer/BioNTech COVID-19 vaccine.

The National Association of Chain Drug Stores and the National Forum for Heart Disease & Stroke Prevention released a video urging Americans to receive flu vaccinations.

The FDA is not required to follow the committee's advice, but it is expected to do so.

Pharmacists can prepare themselves to address patients’ questions and concerns about the COVID-19 vaccines.

A poster presented at the ASHP 2020 Midyear Clinical Meeting & Exhibition highlighted the success of an in-pharmacy pneumococcal immunization campaign.

Pharmacists may be among the first of the prioritized groups to be offered the COVID-19 vaccine once it receives FDA authorization.

A survey conducted by the American Pharmacists Association asked pharmacists if they were ready to receive and administer COVID-19 vaccines.

The first doses of the mRNA COVID-19 vaccine will be delivered in the UK in the next few days, Pfizer announced.

Moderna reported an efficacy rate of 94.1% for its COVID-19 vaccine based on the primary efficacy analysis.

In the wake of a resurgence of measles cases and deaths globally, experts are worried about the decline in vaccinations during the pandemic.

One vaccine dosing regimen for AZD1222 showed 90% efficacy, according to investigators at the University of Oxford.

Pfizer and BioNTech expect to produce up to 50 million doses globally in 2020 and up to 1.3 billion doses by the end of 2021.

Pfizer and BioNTech today announced that their COVID-19 vaccine candidate showed a 95% efficacy rate in the final analysis of its phase 3 study.

Moderna announced today that its messenger RNA vaccine candidate for COVID-19 met the primary endpoint of efficacy, according to the study’s first interim analysis.

As part of a new partnership with HHS, the nation’s largest pharmacy chains—as well as independents and regional chains—will be administering free coronavirus disease 2019 (COVID-19) vaccines when they are available.